Bicara Therapeutics
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC (NCT06788990) | Bicara Therapeutics | 2025-01-28 |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (NCT04429542) | Bicara Therapeutics | 2020-06-01 |
Track Bicara Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.